Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy?

Eur J Heart Fail. 2015 Jul;17(7):647-51. doi: 10.1002/ejhf.296. Epub 2015 May 27.

Authors

Tariq Ahmad¹, Javed Butler²

Affiliations

¹ Section of Cardiology, Yale University School of Medicine, New Haven, CT, USA.
² Division of Cardiology, Stony Brook University, Stony Brook, NY, USA.

PMID: 26018996
DOI: 10.1002/ejhf.296

No abstract available

Publication types

Editorial
Comment

MeSH terms

Coronary Artery Disease / drug therapy*
Factor Xa Inhibitors / therapeutic use*
Heart Failure / drug therapy*
Humans
Myocardial Infarction / prevention & control*
Research Design*
Rivaroxaban / therapeutic use*
Stroke / prevention & control*

Substances

Factor Xa Inhibitors
Rivaroxaban